Daño orgánico en Lupus Eritematoso Sistémico (LES)

Paula Alba

doi:10.47196/rar.v29i3.501

Paula Alba Universidad Nacional de Córdoba, Córdoba, Argentina

DOI: https://doi.org/10.47196/rar.v29i3.501

Palabras clave: editorial, reumatología

Resumen

Las enfermedades autoinmunes sistémicas se caracterizan por una amplia y heterogénea variedad de manifestaciones clínicas. Las medidas propuestas para evaluar el pronóstico en ellas son la actividad de la enfermedad, el daño orgánico (DO) y la calidad de vida. El DO es definido como una pérdida permanente o cambio irreversible de la función de un órgano o sistema como consecuencia de una manifestación clínica de la enfermedad. El daño irreversible puede ser el resultado de la actividad de la enfermedad, el tratamiento recibido para la misma o ambos, y la coexistencia de comorbilidades.

Biografía del autor/a

Paula Alba, Universidad Nacional de Córdoba, Córdoba, Argentina

Profesora asociado en ReumatologíaPostgrado de ReumatologíaCátedra de Medicina

Citas

I. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV .Outcome Measures in Rheumatology. Lupus 2000; 9:322-7.

II. Fischer-Betz R, Schneider M. Connective tissue diseases: evaluation of clinical response. Rheumatology (Oxford) 2008; 47(2):234-5.

III. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.

IV. Gladman DD, Urowitz MB ,Goldsmith CH, , Bacon P, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index in patients with ystemic lupus erythematosus. Arthritis Rheum 1997; 40 (5):809-13.

V. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/ American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 2000; 27(2):373-6.

VI. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10(2):93-6.

VII. Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29(7): 1398-400.

VIII. Cardoso CR, Signorelli FV, Papi JA, Salles GF. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study. Lupus 2008, 17(11): 1042-8.

IX. Mok C C, Ho CT, Wong RW, Lau CS. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1513-19.

X. Danila MI, Pons-Estel GJ, Zhang J, et al. Renal Damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009; 48:542-45.

XI. Sutton EJ, Davidson JE, Bruce IN. The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review. Semin Arthritis Rheum 2013; 43(3):352-61.

XII. Nossent JC. SLICC/ACR damage index in Afro-Caribbean patients patients with systemic lupus erythematosus: changes in and relationship to disease activity, cortico-steroids therapy, and prognosis. J Rheumatol 1998; 25(4):654-9.

XIII. Alarcon GS, McGwin G Jr, Bartolucci AA, et al. Systemic lupus erythematosus in three ethnic groups IX. Differences in damage accrual. Arthritis Rheum 2001; 44(12):2797-806.

XIV. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19 (8):949-56.

XV. Mendoza- Pinto C, Mendez-Martinez S, Soto-Santillán P, et al. Socioeconomic status and organ damage in Mexican systemic lupus erythematosus women. Lupus 2015; 24:1227-32.

XVI. Tam LS, Gladman DD, Hallett DC, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: (9):2142-5.

XVII. Fessler BJ, Alarcon GS, McGwin G Jr, et al. Systemic lupus eryhtematosus in three ethnic groups XVI. Association of hydroxycloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52(5): 1473-80.

XVIII. Akhavan PS, Su J, Lou W, et al. The effect of hydroxycloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2009; 36 (11):2580.